Island Pharmaceuticals Acquires Galidesivir to Target Marburg Virus
Island Pharmaceuticals (ASX: ILA) has acquired the Galidesivir antiviral program from BioCryst Pharmaceuticals, accelerating a prior option agreement after successful due diligence. Galidesivir, a broad-spectrum antiviral with U.S. government R&D funding, will be prioritized for Marburg virus treatment. Island may pursue FDA approval via the Animal Rule, potentially requiring just one more successful animal study. This complements Island’s lead asset, ISLA-101, being repurposed for dengue fever and mosquito-borne diseases.
Island Pharmaceuticals Acquires Galidesivir to Target Marburg Virus